Unbound MEDLINE

A recombinant-based ELISA evaluating the efficacy of netobimin and albendazole in ruminants with naturally acquired fascioliasis. Veterinary journal (London, England : 1997) [Vet J] Journal article

 
TitleA recombinant-based ELISA evaluating the efficacy of netobimin and albendazole in ruminants with naturally acquired fascioliasis.
Author(s)Arias MS, Suárez JL, Hillyer GV, Francisco I, Calvo E, Sánchez-Andrade R, Díaz P, Francisco R, Díez-Baños P, Morrondo P, Paz-Silva A 
InstitutionAnimal Pathology Department, Epidemiology, Zoonoses and Parasitic Diseases, Veterinary Faculty, Santiago de Compostela University, 27002 Lugo, Spain.
SourceVet J 2009 Oct; 182(1):73-8.
MeSHAlbendazole
Animals
Anthelmintics
Antibodies, Helminth
Cattle
Cattle Diseases
Enzyme-Linked Immunosorbent Assay
Fasciola hepatica
Fascioliasis
Feces
Female
Guanidines
Helminth Proteins
Immunoglobulin G
Parasite Egg Count
Random Allocation
Recombinant Proteins
Sensitivity and Specificity
Sheep
Sheep Diseases
Treatment Outcome
AbstractThe therapeutic efficacy of albendazole and netobimin in ruminants with naturally occurring fascioliasis was investigated using a recombinant-based ELISA. The variation in the IgG response against a 2.9-kDa recombinant protein (FhrAPS), termed efficacy index (EI) 1, and the egg-output changes, termed EI 2, were used to evaluate drug efficacy. The values of EI 1 ranged between 0% and 50% in sheep, and between 0% and 30% in cattle after treatment with albendazole and netobimin. Similar EI 2 values were observed in sheep receiving albendazole or netobimin, but the highest values were found in cattle treated with netobimin. The significant reduction in the IgG response to FhrAPS found in this study shows promise in terms of developing alternative methods for evaluating the efficacy of chemotherapy against Fasciola hepatica in grazing ruminants.
Languageeng
Pub Type(s)Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
PubMed ID19524206
  
Advertise on this site.